Carboranyl amino acids for site specific neutron capture therapy of malignant melanoma

Technical Report · Tue Dec 31 04:00:00 EST 1991

OSTI ID:10145813

Kahl, S B

The single most difficult problem yet to be solved for effective clinical use of boron neutron capture therapy (BNCT) in the United States is the development of highly tumor-selective third generation boron compounds. In this context, the boronated amino acids and peptides would be a significant step toward this goal. Our preliminary in vitro finding that carboranylalanine is a highly potent neutron sensitizer strongly suggests that this amino acid is a most desirable third generation compound, and our development of both chiral and achiral synthesis for its production are a necessary prerequisite for advancement of the field in this area. We further believe that insertion of this amino acid into carefully selected peptides will provide substances able to a target a much wider variety of malignancies than just melanoma. It seems clear that further investigations into this promising field are warranted if BNCT is to achieve clinical acceptability.

• Research Organization: California Univ., San Francisco, CA (United States)
• Sponsoring Organization: USDOE, Washington, DC (United States)
• DOE Contract Number: FG03-89ER60873
• OSTI ID: 10145813
• Report Number(s): DOE/ER/60873--T2; ON: DE92013811
• Country of Publication: United States
• Language: English

Related Subjects

37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CHEMISTRY
400201
550603
62 RADIOLOGY AND NUCLEAR MEDICINE
ALANINES
AMINO ACIDS
BIOASSAY
CARBON 13
CARBORANES
CHEMICAL AND PHYSICOCHEMICAL PROPERTIES
COMPARATIVE EVALUATIONS
EXTERNAL RADIATION IN THERAPY
MELANOMAS
NEUTRON CAPTURE THERAPY
NUCLEAR MAGNETIC RESONANCE
PROGRESS REPORT